Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rishi Singh

Ophthalmology Boston, MA Medical Doctor

NPI 1750447660 CMS profile 306129

243 Charles St, Boston, MA 02114

Open in the dashboard

General payments

$1,689,674

1,020 records reported · program years 2019–2025

Research payments

$198,783

Paid to them · 136 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$787,070 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Rishi Singh of Boston, MA is reported in the CMS Open Payments database as having received $1,689,674 across 1,020 general payments and $198,783 in research payments paid to them. Separately, studies naming them as principal investigator received $787,070 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $201,187 115
2025 Research $25,074 33
2024 General $248,636 170
2024 Research $86,441 39
2023 General $455,984 226
2023 Research $15,574 17
2022 General $242,280 175
2022 Research $10,833 15
2021 General $191,267 114
2021 Research $32,640 19
2020 General $118,016 73
2020 Research $14,663 4
2019 General $232,303 147
2019 Research $13,559 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rishi Singh
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Rishi Singh were reported at $201,187. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Rishi Singh Ophthalmology median Middle half National median
2019 $232,303 $258 $104–$655 $163
2020 $118,016 $126 $45–$321 $114
2021 $191,267 $205 $76–$534 $132
2022 $242,280 $266 $100–$678 $149
2023 $455,984 $308 $117–$745 $160
2024 $248,636 $340 $127–$846 $164
2025 $201,187 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Apellis Pharmaceuticals, Inc. $307,172 166 payments
  2. Regeneron Healthcare Solutions, Inc. $247,218 129 payments
  3. Genentech USA, Inc. $146,524 83 payments
  4. Alcon Vision LLC $108,731 88 payments
  5. Genentech, Inc. $101,496 34 payments
  6. Novartis Pharmaceuticals Corporation $91,774 56 payments
  7. EyePoint Pharmaceuticals US, Inc. $73,642 44 payments
  8. Carl Zeiss Meditec, Inc. $70,331 46 payments
  9. Hoffmann-La Roche Limited $62,544 23 payments
  10. AbbVie, Inc. $49,788 30 payments
  11. Other $430,455 321 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $873,276 292 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $552,367 122 payments
  3. Travel and Lodging $120,075 231 payments
  4. Honoraria $64,855 18 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $38,408 7 payments
  6. Food and Beverage $27,814 343 payments
  7. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $12,600 4 payments
  8. Gift $280 3 payments
Products named General payments · program years 2019–2025
  1. EYLEA $198,854 120 payments
  2. Syfovre $180,496 104 payments
  3. VABYSMO $176,670 60 payments
  4. BEOVU $86,664 41 payments
  5. EYLEA HD $84,919 44 payments
  6. Constellation $67,319 32 payments
  7. Izervay $55,672 43 payments
  8. Lucentis $43,298 23 payments
  9. Cimerli $38,515 12 payments
  10. OZURDEX $34,735 18 payments
  11. Other $476,455 400 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $109,235 64 payments
  2. Regeneron Pharmaceuticals, Inc. $63,844 63 payments
  3. Alimera Sciences, Inc. $14,750 5 payments
  4. Novartis Pharma AG $10,115 3 payments
  5. Novartis Pharmaceuticals Corporation $840 1 payment

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$3,781

Medicare's payments for the services billed

Medicare patients

44

Average age 77

Services billed

87

21 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 57%
Diabetes 34%
Ischemic heart disease 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Syfovre
  • Apellis Pharmaceuticals, Inc. $49,637
$49,637 — —
Izervay
  • Astellas Pharma US Inc $40,346
  • Astellas Pharma Global Development $6,543
$46,889 — —
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $30,885
  • Regeneron Pharmaceuticals, Inc. $1,172
$32,057 — —
VABYSMO
  • Genentech USA, Inc. $15,669
  • Genentech, Inc. $10,205
$25,874 — —
OZURDEX
  • AbbVie, Inc. $10,275
$10,275 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

1,156 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record